ondasdechoque.org
PT-BR

Multiple tendon conditions · Review · 2024

Does shockwave ease arm and shoulder tendon pain more than placebo?

In this review of 18 trials, pain 3 months after shockwave was about 1.5 points lower than after a placebo treatment. Shoulder function scores also improved more. Results varied between tendons, wave types and strengths.

Helped more than placebo at 3 months
placebo-controlled trials, with 1,351 people
18
tendon areas: shoulder, elbow, biceps, finger
4
months after treatment, when pain was compared
3

Good to know: Most trials were in shoulder tendon pain or tennis elbow (8 each). Results shown are at about 3 months.

The paper gives two different totals: 18 trials with 1,351 people overall, and 16 trials with 1,751 people for the pain results.

Xiong Y, Wen T, Jin S, et al. Frontiers in Medicine, 2024 · Read the paper ↗

How this study worked

16 studies1,751 peopleOne answer
A review gathers earlier studies to answer one question.

What happened

trials in the pain result
16
people
1,751
Compared with
Placebo (sham) shockwave

Arm and shoulder tendon pain at 3 months

Difference from placebo in pain score points; below zero favours shockwave

Three months after treatment, pain was about 1.5 points lower with shockwave than with placebo, with a likely range of about 0.5 to 2.5 points.
Show the numbers
Difference (pain score points)likely range
Pain at 3 months, all tendons−1.45−2.46 to −0.45

What the trials used

Energy and session ranges
Eighteen RCTs covered rotator cuff, lateral elbow, long-head biceps and finger tendon disorders. Table 1 lists energy from 0.006 to 0.32 mJ/mm² when reported, 1,500–6,000 pulses in examples, and varying schedules from one session to five sessions. Authors define low EFD <0.12 mJ/mm² and high EFD 0.12–0.38 mJ/mm², leaving exactly 0.12 boundary classification ambiguous. Some radial trials report no EFD or maximum tolerance.
Control conditions and co-interventions
Eligibility required placebo/sham control. Table 1 lists placebo comparators; protocols varied in local anesthesia or oral analgesia, and review authors state these could contribute heterogeneity.

Who took part

1,351 people with arm or shoulder tendon pain in 18 trials: 740 had shockwave and 611 a placebo. Most had shoulder tendon pain or tennis elbow.

Side effects

Some trials reported brief pain and skin reactions that usually settled after treatment. A few people could not tolerate treatment, got worse or dropped out. No serious long-term side effects were reported.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Eighteen placebo-controlled RCTs included 1,351 patients with upper-limb tendinopathy: 740 in ESWT groups and 611 in placebo groups. Diagnoses and outcome subgroup counts vary, and the article reports internally inconsistent denominators in its outcome sections.

Visual analogue scale (VAS)12 reported outcomes
01
3 months; closest assessment 1–3 months used when 3-month unavailable

Pain across upper-limb tendinitis

Visual analogue scale (VAS) Mean difference (VAS points; as reported)

MD-1.45CI 95% -2.46 to -0.45p <0.05

ESWT versus placebo/sham across included upper-limb conditions

16 studies · 1,751 participants in this estimate

-2.8Equal results 00.3

The review reports a pooled pain difference at 3 months favoring ESWT, with very high heterogeneity (I²=95%).

Analysis details and source

The stated 16-study/1,751-participant contribution conflicts with the review-wide 18 RCTs/1,351 people and with the 1,193 people in the later 16-study modality subgroup.

02
3 months

Reported test for ESWT modality subgroup differences

Visual analogue scale (VAS) Mean difference (VAS points; as reported)

MD-1.45CI 95% -2.46 to -0.45p = 0.04

Ambiguously reported subgroup-difference statistic; not verified as a direct radial-versus-focused effect

-2.8Equal results 00.3

The source prints −1.45 (95% CI −2.46 to −0.45), I²=77.4%, p=.04 as a subgroup-difference result, but this duplicates the overall estimate in §3.4.1 and the same paragraph says no significant modality difference. This is not presented as a verified direct radial-versus-focused treatment effect.

Analysis details and source

Preserve the source inconsistency: exact duplicate of the overall pooled estimate, alongside contradictory prose. Do not infer a treatment contrast.

03
3 months

Pain by energy subgroup

Visual analogue scale (VAS) Mean difference (VAS points; as reported)

MD-2.25CI 95% -3.79 to -0.71p = 0.004

High-energy ESWT versus placebo/sham

-4.2Equal results 00.5

The review reports a high-energy subgroup estimate favoring ESWT.

Analysis details and source

The same section reports low-energy MD −1.74 (95% CI −3.33 to −0.14), P=0.03, then calls it nonsignificant versus control. The text is internally contradictory; low-energy effect not charted as a resolved result.

06
6 months

Overall pain at six months

Visual analogue scale (VAS) Source-reported MD and interval; not charted because internally inconsistent

Results §3.4.1 prints a six-month VAS MD of −0.29 (95% CI −1.33 to −0.74), I²=0%, p=.58 (the section's 16 studies/1,751 participants describe the VAS analyses as a whole), while describing improvement at both 3 and 6 months. The interval does not contain the point estimate and conflicts with the nonsignificant p-value; exact source text is preserved and no corrected estimate is inferred.

Analysis details and source

Conflicting source statistic is retained as qualitative text and intentionally not encoded as a numeric effect chart.

07
3 months

VAS in calcific tendinitis

Visual analogue scale (VAS) MD

MD-2.31CI 95% -6.48 to 1.86p = 0.28

ESWT vs placebo/sham within the reported subgroup

I²=98%

-7.5Equal results 02.9

Source-reported VAS estimate in calcific tendinitis: -2.31 (95% CI -6.48 to 1.86), p=.28; heterogeneity I²=98%.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated. §3.4.2 pools only low-energy ESWT (EFD < 0.12 mJ/mm²) trials for both calcification subgroups (5 studies, 380 participants).

08
3 months

VAS in non-calcific tendinitis

Visual analogue scale (VAS) MD

MD-1.55CI 95% -3.46 to 0.36p = 0.11

ESWT vs placebo/sham within the reported subgroup

I²=67%

-3.9Equal results 00.8

Source-reported VAS estimate in non-calcific tendinitis: -1.55 (95% CI -3.46 to 0.36), p=.11; heterogeneity I²=67%.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated. §3.4.2 pools only low-energy ESWT (EFD < 0.12 mJ/mm²) trials for both calcification subgroups (5 studies, 380 participants).

09
3 months

VAS in rotator-cuff tendinitis

Visual analogue scale (VAS) MD

MD-0.8CI 95% -1.47 to -0.12p = 0.02

ESWT vs placebo/sham within the reported subgroup

I²=0%

-1.6Equal results 00.2

Source-reported VAS estimate in rotator-cuff tendinitis: -0.8 (95% CI -1.47 to -0.12), p=.02; heterogeneity I²=0%.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated.

10
3 months

VAS in lateral epicondylitis

Visual analogue scale (VAS) MD

MD-0.92CI 95% -1.57 to -0.28p = 0.005

ESWT vs placebo/sham within the reported subgroup

I²=69%

-1.8Equal results 00.2

Source-reported VAS estimate in lateral epicondylitis: -0.92 (95% CI -1.57 to -0.28), p=.005; heterogeneity I²=69%.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated.

11
3 months

VAS in trigger finger

Visual analogue scale (VAS) MD

MD-0.47CI 95% -1.95 to 1.281p = 0.53

ESWT vs placebo/sham within the reported subgroup

-2.3Equal results 01.7

Source-reported VAS estimate in trigger finger: -0.47 (95% CI -1.95 to 1.281), p=.53; heterogeneity not stated.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated.

12
3 months

VAS in focused ESWT subgroup

Visual analogue scale (VAS) MD

MD-0.73CI 95% -1.16 to -0.29p = 0.001

ESWT vs placebo/sham within the reported subgroup

I²=46%

-1.3Equal results 00.1

Source-reported VAS estimate in focused ESWT subgroup: -0.73 (95% CI -1.16 to -0.29), p=.001; heterogeneity I²=46%.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated.

13
3 months

VAS in radial ESWT subgroup

Visual analogue scale (VAS) MD

MD-2.59CI 95% -4.27 to -0.91p <0.01

ESWT vs placebo/sham within the reported subgroup

I²=95%

-4.8Equal results 00.5

Source-reported VAS estimate in radial ESWT subgroup: -2.59 (95% CI -4.27 to -0.91), p<.01; heterogeneity I²=95%.

Analysis details and source

Source-reported subgroup estimate. Preserve any inconsistency with surrounding article text; do not reinterpret as a direct treatment contrast unless explicitly stated.

14
3 months

VAS in low-energy ESWT subgroup

Visual analogue scale (VAS) MD

MD-1.74CI 95% -3.33 to -0.14p = 0.03

ESWT vs placebo/sham within the reported subgroup

I²=95%

-3.7Equal results 00.4

Section 3.4.5 reports MD −1.74 (95% CI −3.33 to −0.14), I²=95%, p=.03, but the same passage says low-energy ESWT was “not significant compared with the control group.” The source therefore contains an explicit significance contradiction; retain both statements without resolving it.

Analysis details and source

The estimate and p value conflict with the article’s adjacent verbal statement that this subgroup was not significant versus control. Both are source-reported; do not select one as authoritative.

Constant–Murley score (CMS)1 reported outcome
04
3 months

Shoulder function in rotator cuff tendinitis

Constant–Murley score (CMS) Mean difference (CMS points; as reported)

MD7.56CI 95% 3.69 to 11.43p <0.001

ESWT versus placebo/sham

6 studies · 352 participants in this estimate

-1.4Equal results 012.8

CMS favored ESWT overall. Subgroups favored ESWT for calcific cases (MD 5.76, 95% CI 0.92 to 10.61) and non-calcific cases (MD 12.20, 5.21 to 19.18).

Analysis details and source

The review also reports high-energy MD 18.47 (13.71–23.23) and low-energy MD 7.56 (3.69–11.43), with subgroup difference MD 11.91 (8.91–14.91), P<0.001; small, heterogeneous evidence base. The low-energy subgroup result is identical to the overall estimate (same MD, interval and I²=37%), which the source does not explain.

Grip strength (GS)1 reported outcome
05
3 months

Grip strength in lateral epicondylitis

Grip strength (GS) Mean difference (grip strength; unit not stated in the review)

MD2.38CI 95% -0.43 to 5.2p = 0.10

ESWT versus placebo/sham

4 studies · 227 participants in this estimate

-1.1Equal results 05.9

The pooled grip-strength result was not statistically significant; the interval includes no difference.

Analysis details and source

The authors rate evidence moderate because of small sample and wide confidence interval. Four trials did not report EFD.

How treatment was delivered
Energy and session ranges

Eighteen RCTs covered rotator cuff, lateral elbow, long-head biceps and finger tendon disorders. Table 1 lists energy from 0.006 to 0.32 mJ/mm² when reported, 1,500–6,000 pulses in examples, and varying schedules from one session to five sessions. Authors define low EFD <0.12 mJ/mm² and high EFD 0.12–0.38 mJ/mm², leaving exactly 0.12 boundary classification ambiguous. Some radial trials report no EFD or maximum tolerance.

Control conditions and co-interventions

Eligibility required placebo/sham control. Table 1 lists placebo comparators; protocols varied in local anesthesia or oral analgesia, and review authors state these could contribute heterogeneity.

HARMS & TOLERABILITY

Transient pain and local reactions were reported in some studies; symptoms generally resolved after treatment. Some participants could not tolerate treatment, worsened or withdrew. No serious long-term adverse effects were reported; event rates were not pooled or fully quantified.

LIMITS OF THE ANALYSIS

Pain estimates had high heterogeneity; diagnosis-specific subgroups were small, some intervention parameters were missing, and three studies had incomplete outcome data.

The article reports conflicting study and participant denominators (18/1,351 overall; 16/1,751 for VAS; 16/1,193 for modality analyses), and contradictory significance statements around the 6-month VAS, modality subgroup difference and low-energy pain. Values are retained as reported without resolving the conflict.

Forest-plot images were not available for independent visual verification; values come from the text and tables.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Pain estimates had high heterogeneity; diagnosis-specific subgroups were small, some intervention parameters were missing, and three studies had incomplete outcome data.
  • The article reports conflicting study and participant denominators (18/1,351 overall; 16/1,751 for VAS; 16/1,193 for modality analyses), and contradictory significance statements around the 6-month VAS, modality subgroup difference and low-energy pain. Values are retained as reported without resolving the conflict.
  • Forest-plot images were not available for independent visual verification; values come from the text and tables.
Research review

Source-linked critical reading

Systematic review with meta-analysis

Reading depthMaterial consulted
Technical source record

Read complete full-text XML; verified 2 raw tables and 12 figure captions; checked population counts, energy cutoffs, study-level regimens, VAS/CMS/grip subgroup estimates, harms, GRADE, denominators, internal contradictory p/CI/significance statements, limitations and end matter. Figure pixels were unavailable; the XML lists no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Systematic review/meta-analysis of 18 RCTs across four upper-limb diagnoses, searched in five databases through December 2023 and registered CRD42023403594. The review required placebo/sham controls and rated VAS/CMS/GS evidence with GRADE.

Participants

The Results section reports 1,351 people across the 18 included RCTs, 740 assigned to ESWT and 611 to placebo. Diagnoses included eight rotator-cuff, eight lateral-epicondylitis, one long-head-biceps and one finger-tendon trial. Later outcome subsections report inconsistent larger denominators.

Intervention protocols

Focused and radial ESWT varied in energy, pulse count, sessions and schedule; local anesthesia/oral analgesia was used in some trials. Authors classify low <0.12 and high 0.12–0.38 mJ/mm². Five of 18 trials lacked precise EFD data; radial EFD was often unavailable.

Comparators

The review included sham/placebo-controlled trials. Comparators and blinding details vary; pooled estimates represent ESWT versus sham across heterogeneous upper-limb conditions, not one treatment protocol.

Outcomes

VAS assessed pain, Constant–Murley assessed rotator-cuff function, and grip strength assessed lateral-elbow function. The review’s method says closest 1–3-month timepoints were used when exact 3-month data were unavailable. Safety was described narratively. Additional Results subgroup values: at 6 months, overall VAS MD −0.29 (95% CI −1.33 to −0.74), I²=0%, p=.58 (the section's 16 studies/1,751 participants describe all VAS analyses); the interval excludes its point estimate and conflicts with p and prose. Calcific and non-calcific subgroup estimates were −2.31 (−6.48 to 1.86), p=.28, and −1.55 (−3.46 to .36), p=.11. Diagnosis subgroups: rotator cuff −.80 (−1.47 to −.12), p=.02; lateral epicondylitis −.92 (−1.57 to −.28), p=.005; trigger finger −.47 (−1.95 to 1.281), p=.53 (upper CI bound unusual as printed). Focused and radial subgroup estimates were −.73 (−1.16 to −.29), p=.001, and −2.59 (−4.27 to −.91), p<.01. Low-energy subgroup MD −1.74 (−3.33 to −.14), p=.03, conflicts with prose calling it nonsignificant. The reported modality subgroup-difference statistic −1.45 duplicates the overall value and is not treated as a verified direct effect.

Comparative findings

The pooled 3-month pain estimate was MD −1.45 (95% CI −2.46 to −0.45; I²=95%), but reported study/patient totals conflict. Radial and focused subgroup estimates favored treatment, while the text contradicts itself about whether their subgroup difference is significant. High-energy pain results favored ESWT; low-energy significance is internally inconsistent. CMS favored ESWT at 3 months, while grip-strength difference was not significant.

Harms

The review reports transient pain, swelling, erythema, petechiae and small hematomas in some studies, usually resolving after treatment; some participants could not tolerate treatment, had worsening symptoms or withdrew. No serious long-term adverse effects were reported, but event denominators and collection methods are not supplied in the main text.

Limitations and source inconsistencies

High VAS heterogeneity (I²>80%), small condition-specific subsets, missing energy/session parameters, three trials with incomplete outcome data, and mixed diagnosis/protocols limit confidence. The source says 18 RCTs/1,351 participants overall, but 16 studies/1,751 for VAS and 16/1,193 for modality subgroups. It reports a 6-month CI entirely below zero alongside P=0.58, and contradictory significance statements for radial/focused and low-energy pain results.

Applicability

The review offers hypothesis-generating findings for upper-limb tendinopathy, with stronger evidence for short-term pain/function than for finger or biceps conditions. It cannot support a universal radial-over-focused recommendation given its internally conflicting subgroup interpretation.

Research needs

Trials should report arm-level denominators, exact device and EFD, pulse/session schedule, co-interventions, standardized diagnosis and complete harms. Reviews should reconcile source counts, prespecify subgroup interactions and present consistent estimates/intervals.

THE ORIGINAL SOURCE

Read the original article.

Efficacy and safety of extracorporeal shock wave therapy for upper limb tendonitis: a systematic review and meta-analysis of randomized controlled trials.

Xiong Y, Wen T, Jin S, Lin L, Shao Q, Peng Y, Zheng Q, Li W. · Frontiers in medicine · 2024

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →